|Dr. Allen W. Davidoff||Founder, CEO, Pres & Director||N/A||N/A||N/A|
|Mr. James Neville Fairbairn||Chief Financial Officer||N/A||N/A||1963|
|Dr. Alan F. Moore||Exec. Consultant of Clinical & Regulatory Affairs||N/A||N/A||1948|
|Charlotte May||Corp. Sec.||N/A||N/A||N/A|
XORTX Therapeutics Inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. It has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. The company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. In addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. The company has strategic alliance with Teijin Pharma Limited to develop TMX-049, a xanthine oxidoreductase. XORTX Therapeutics Inc. is headquartered in Calgary, Canada.
XORTX Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.